<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>研发客研究院 | wechat-feeds</title><link>http://MzA5OTQyNjE3NA.favicon.privacyhide.com/favicon.ico</link><description>独立报告、专业分析、深度解读</description><managingEditor> (hellodword)</managingEditor><pubDate>Fri, 16 Apr 2021 07:23:21 +0800</pubDate><image><url>http://MzA5OTQyNjE3NA.favicon.privacyhide.com/favicon.ico</url><title>研发客研究院 | wechat-feeds</title><link>http://MzA5OTQyNjE3NA.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>China Regulations Tracker: Feb 2021</title><link>https://mp.weixin.qq.com/s/y8Ef0MCbAhMEHVvCoSdh_A</link><description></description><content:encoded><![CDATA[China Regulations Tracker: Feb 2021]]></content:encoded><pubDate>Thu, 15 Apr 2021 16:38:30 +0800</pubDate></item><item><title>China Biotech Fundraising Tracker: Feb 2021</title><link>https://mp.weixin.qq.com/s/DOL57XfwDwuYmH43jFnKZQ</link><description></description><content:encoded><![CDATA[China Biotech Fundraising Tracker: Feb 2021]]></content:encoded><pubDate>Sun, 11 Apr 2021 19:54:27 +0800</pubDate></item><item><title>凯因科技：差异化营销策略能否化解产品困局？ | SWOT分析</title><link>https://mp.weixin.qq.com/s/teEFahEAcXTFMM5mz_rffg</link><description></description><content:encoded><![CDATA[凯因科技：差异化营销策略能否化解产品困局？ | SWOT分析]]></content:encoded><pubDate>Fri, 09 Apr 2021 00:30:36 +0800</pubDate></item><item><title>China Licensing Deals Tracker: Feb 2021</title><link>https://mp.weixin.qq.com/s/GkZEATUmI1d8RyGG__OrXw</link><description></description><content:encoded><![CDATA[China Licensing Deals Tracker: Feb 2021]]></content:encoded><pubDate>Mon, 05 Apr 2021 21:21:26 +0800</pubDate></item><item><title>PDC：偶联多肽攻击实体瘤，国内有4家研发 | 分析</title><link>https://mp.weixin.qq.com/s/JuAlpy2iRgdZX14a1jwgTA</link><description></description><content:encoded><![CDATA[PDC：偶联多肽攻击实体瘤，国内有4家研发 | 分析]]></content:encoded><pubDate>Fri, 02 Apr 2021 09:26:00 +0800</pubDate></item><item><title>New Regulations for Post-Market Drug Changes</title><link>https://mp.weixin.qq.com/s/UzYgeWTDFIJB4nYDsNQRqw</link><description></description><content:encoded><![CDATA[New Regulations for Post-Market Drug Changes]]></content:encoded><pubDate>Wed, 31 Mar 2021 13:34:26 +0800</pubDate></item><item><title>海和药物：专注小分子抗肿瘤新药 ｜SWOT分析</title><link>https://mp.weixin.qq.com/s/QEuDZ2ftuC_HdHeCTwxVVw</link><description></description><content:encoded><![CDATA[海和药物：专注小分子抗肿瘤新药 ｜SWOT分析]]></content:encoded><pubDate>Tue, 30 Mar 2021 20:50:33 +0800</pubDate></item><item><title>China Market Approval Tracker: Feb 2021</title><link>https://mp.weixin.qq.com/s/9rPLXf_bV_qLhlaGy9Kmrg</link><description></description><content:encoded><![CDATA[China Market Approval Tracker: Feb 2021]]></content:encoded><pubDate>Tue, 30 Mar 2021 09:15:52 +0800</pubDate></item><item><title>冠科美博：许可引进和授权合作双向开发 | SWOT分析</title><link>https://mp.weixin.qq.com/s/0jgi57jcVDLxSVm6WT2F0g</link><description></description><content:encoded><![CDATA[冠科美博：许可引进和授权合作双向开发 | SWOT分析]]></content:encoded><pubDate>Sun, 28 Mar 2021 13:27:57 +0800</pubDate></item><item><title>科济：CAR-T治疗实体瘤的机会与风险 | SWOT分析</title><link>https://mp.weixin.qq.com/s/Ml0NpDwtO3ZtRwJTE7FtZw</link><description></description><content:encoded><![CDATA[科济：CAR-T治疗实体瘤的机会与风险 | SWOT分析]]></content:encoded><pubDate>Thu, 25 Mar 2021 17:44:09 +0800</pubDate></item></channel></rss>